Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are ...
Cyst: Cystectomy; Preop.: Preoperative radiotherapy. Radical cystectomy continues to be the treatment of choice for muscle-invasive bladder cancer. However, its treatment end results are still ...
Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...
The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...
The magnitude of errors due to organ motion, target delineation and treatment setup are different for different regions of the bladder, suggesting that anisotropic margins should be used; CTV to PTV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback